Jared Holles from Missouo joining us once again. Jared, good to have you back on. What does the in plain English, what does this 15% tariff cap mean for your companies that you follow.>> Great to see you, Brian. Thanks a lot for having me. Yeah, I mean, it's a it's a piece of the puzzle.I think we're trying to put this mosaic together to kind of determine, you know, what the economic policies are going to be with respect to this industry. And the 15% I think is important in the context of you know as you al ...

On Friday, Takeda Pharmaceutical Co Ltd's TAK stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.'s IONS Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.Investors should note that Takeda also has a hereditary angioedema prevention drug, ...

Core Viewpoint - Berger Montague is investigating potential securities fraud claims against Hims & Hers Health Inc. following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and regulatory non-compliance [1][3][4]. Group 1: Legal Investigation - Investors who acquired Hims & Hers securities between April 29, 2025, and June 22, 2025, have until August 25, 2025, to seek appointment as lead plaintiff representative [2]. - The lawsuit claims that Hims & Hers made materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk [4]. Group 2: Market Reaction - Following the announcement of the partnership termination, Hims & Hers shares fell by over 34% in intraday trading, indicating significant investor concern over regulatory compliance and reputational risks [3].

Core Insights - Shifts in fundamental ranking scores can reveal deeper insights into a company's trajectory beyond daily stock price movements [1] Group 1: Company Performance - Tesla's Quality score dropped significantly by 16.14 points from 73.14 to 57.00, indicating potential issues in profitability and stability [3] - Taiwan Semiconductor Manufacturing Company saw a remarkable increase in its Growth score, rising by 58.05 points from 29.96 to 88.01, driven by expectations around AI and high-performance computing [5] - American Express's Quality score surpassed the 50th percentile, reflecting improved financial stability and operational efficiency [8] - AbbVie's Momentum score moved past the 50th percentile, suggesting increased investor interest following positive trial results for its drug Rinvoq [10][11] - Nucor's Quality score fell sharply by 30.99 points from 78.71 to 47.72, indicating potential financial health issues in the steel industry [12] Group 2: Market Dynamics - Tesla increased the price of its Cybertruck by $15,000 to $114,990 amid rising inventories and slowing sales [4] - U.S. officials are considering equity stakes in chipmakers like Taiwan Semiconductor, which could impact ownership and operations [6] - Nucor and other U.S. steelmakers successfully advocated for tariffs, with the Commerce Department imposing 50% duties on over 400 steel and aluminum products [13] Group 3: Investment Implications - The changes in fundamental scores for companies like Tesla and Taiwan Semiconductor highlight the volatility in mega-cap fundamentals, which may not be immediately reflected in stock prices [15] - The crossing of percentile thresholds by AbbVie and American Express signals important shifts in market leadership [15]

Core Insights - Gilead Sciences, Inc. (GILD) shares fell 2.2% following CVS Health's decision not to include GILD's new HIV prevention drug, Yeztugo, in its commercial plans for the time being [1][8] - CVS Health's decision was influenced by clinical, financial, and regulatory factors, and Yeztugo will not be covered under its Affordable Care Act formularies [2] - GILD is negotiating with CVS regarding Yeztugo, which has a U.S. list price exceeding $28,000 annually [2] Gilead's Product Developments - Yeztugo received FDA approval in June 2025 for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg, and it is the first and only twice-yearly HIV PrEP option available in the U.S. [3][5] - GILD aims to secure 75% insurer coverage for Yeztugo by year-end 2025 and 90% within 12 months [3] Market Context - Currently, GILD markets two FDA-approved daily oral medications for PrEP: Truvada and Descovy [4] - GILD's shares have increased by 25.7% year-to-date, outperforming the industry growth of 4% [5] Acquisition Activity - Gilead's subsidiary, Kite, announced an agreement to acquire Interius BioTherapeutics for $350 million, which focuses on developing in vivo CAR therapeutics [7][9] - This acquisition is expected to impact GILD's earnings per share by approximately $0.23-$0.25 [8][9] Competitive Landscape - Gilead currently holds a Zacks Rank 3 (Hold), while CorMedix (CRMD) and ANI Pharmaceuticals (ANIP) have better rankings with Zacks Rank 1 (Strong Buy) [10] - CorMedix's earnings per share estimates have increased significantly, and its shares have rallied 49.1% year-to-date [11] - ANI Pharmaceuticals has also seen a slight increase in earnings estimates and a year-to-date share increase of 29.4% [12]

Core Viewpoint - Phathom Pharmaceuticals, Inc. (PHAT) has shown a significant price increase of 21% over the past four weeks, with a mean price target of $20.5 indicating an upside potential of 87.2% from the current price of $10.95 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $8.02, indicating variability among analysts [2] - The lowest estimate is $5.00, suggesting a potential decline of 54.3%, while the highest estimate is $29.00, indicating a potential increase of 164.8% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 4.2%, with one estimate moving higher and no negative revisions [12] - PHAT currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after by investors, they can mislead more often than guide, and should not be the sole basis for investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Insights - AbbVie (ABBV) maintains a strong position in the immunology market, bolstered by robust sales of its new drugs, Rinvoq and Skyrizi, which are compensating for the decline in Humira's sales due to patent expiration and biosimilar competition [1][5] Group 1: Product Performance - Rinvoq has shown impressive sales across all approved indications, particularly in inflammatory bowel diseases like ulcerative colitis and Crohn's disease, with potential approvals for five new indications expected to enhance sales further [2][5] - In the first half of 2025, Rinvoq generated sales of $3.7 billion, marking a 49% year-over-year increase, and is projected to reach approximately $8 billion for the full year [5][9] - Positive results from the pivotal phase III UP-AA clinical program for Rinvoq in treating severe alopecia areata were reported, with 45.2% and 55% of patients achieving significant hair coverage at different dosages, compared to only 1.5% with placebo [3][9] Group 2: Regulatory and Future Prospects - AbbVie plans to submit a regulatory application for Rinvoq for alopecia areata in late 2025, with additional phase III data for vitiligo expected in the same year [4] - The anticipated approvals for Rinvoq in new indications could potentially add around $2 billion to peak-year sales [5] Group 3: Competitive Landscape - The market for alopecia areata treatments is highly competitive, with established players like Eli Lilly and Incyte's Olumiant, which generated $475.2 million in sales in the first half of 2025 [6] - Pfizer's Litfulo, approved for alopecia areata, is also in late-stage development for vitiligo, indicating increasing competition in the market [7] Group 4: Financial Performance and Valuation - AbbVie shares have increased by 17.9% year-to-date, contrasting with a 1.6% decline in the industry [8] - AbbVie is trading at a premium valuation, with a price/earnings (P/E) ratio of 15.54, above the industry average of 14.64 and its five-year mean of 12.69 [10] - The Zacks Consensus Estimate for AbbVie's 2025 earnings has slightly decreased from $12.03 to $12.02 per share, while the estimate for 2026 has risen from $14.08 to $14.31 [11]

Core Insights - The partnership between ViRx@Stanford and Fifty1 AI Labs aims to enhance global health security by repurposing existing drugs into antiviral therapies through AI technology [1][2][3] - The initiative, named "BE READI!", focuses on proactive measures to prepare for and respond to emerging pandemics, emphasizing the need for rapid development of antiviral treatments [2][5] - The collaboration is backed by significant funding, including a US$69 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), which supports the development of outpatient antiviral cocktails [4] Company Overview - ViRx@Stanford is dedicated to advancing antiviral drug development and enhancing biosecurity, leveraging cutting-edge AI to accelerate pharmaceutical innovation [6] - Fifty1 AI Labs specializes in AI-driven drug repurposing, focusing on off-patent compounds to create cost-effective therapies that improve patient outcomes [7] Strategic Goals - The partnership aims to build a scalable model for pandemic response, integrating AI and repurposed therapeutics to ensure rapid and equitable access to life-saving treatments [5] - The initiative draws lessons from past pandemics, including the COVID-19 pandemic, which resulted in approximately 10 million deaths, and aims to mitigate similar mortality rates in future outbreaks [3]

Core Insights - Eli Lilly and Company (LLY) is a significant player in the diabetes and obesity drug market, primarily due to the success of its GLP-1 therapies, Mounjaro and Zepbound, which are facing competition from Novo Nordisk's semaglutide medicines [1][2] - The obesity market is projected to grow to $100 billion by 2030, leading to intense competition among key players [2] - Lilly is actively investing in obesity treatments, with several new molecules in clinical development, including orforglipron and retatrutide [3][9] Company Developments - Lilly has reported positive data from two phase III studies on orforglipron, showing significant reductions in A1C and weight among participants [4] - Despite the promising data, the weight loss results from orforglipron fell short of investor expectations, leading to concerns about its market potential [5][6] - Lilly plans to file regulatory applications for orforglipron in obesity by Q4 2025 and for type II diabetes in H1 2026 [7] Competitive Landscape - Other companies, such as Amgen and Viking Therapeutics, are also developing GLP-1-based candidates, intensifying competition in the obesity treatment space [12][16] - Novo Nordisk is advancing its pipeline with an oral version of Wegovy and other next-generation candidates [16] Financial Performance - Lilly's stock has declined by 7.6% this year, contrasting with a 0.2% increase in the industry [17] - The company's stock is currently trading at a price/earnings ratio of 25.29, higher than the industry average of 14.64, but below its 5-year mean of 34.54 [19] Earnings Estimates - Earnings estimates for Lilly have increased for 2025 and 2026, indicating positive market sentiment despite recent setbacks [21]

Core Insights - AbbVie has a strong immunology franchise with blockbuster drugs and has also developed a substantial oncology franchise with key products like Imbruvica and Venclexta [1] Oncology Franchise Development - AbbVie and Genmab's Epkinly was approved for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, while Emrelis was approved for non-squamous non-small cell lung cancer [2] - The acquisition of Immunogen added Elahere to AbbVie's oncology portfolio, contributing to double-digit revenue growth for Elahere and Epkinly in the first half of 2025 [2] - AbbVie's oncology segment generated $3.3 billion in revenue in the first half of 2025, a 4.2% increase year over year, driven by Venclexta and new drugs [3] Innovation in Oncology - AbbVie is enhancing its oncology portfolio with antibody-drug conjugates (ADCs), which are seen as a disruptive innovation in cancer treatment [4] - The company has two ADCs in its commercial portfolio and two additional next-generation ADCs in late-stage development, along with others in early-stage development [4] Pipeline and Growth Potential - A key candidate in AbbVie's oncology pipeline is etentamig/ABBV-383, targeting relapsed/refractory multiple myeloma [5] - Despite competitive pressure on Imbruvica, AbbVie's oncology business is well-positioned for growth in the coming years [5] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, Bristol-Myers, and Pfizer, with AstraZeneca's oncology sales comprising around 43% of total revenues and growing 16% in the first half of 2025 [6] - Merck's Keytruda accounts for about 50% of its pharmaceutical sales, with a 6.6% sales increase to $15.1 billion in the first half of 2025 [7] - Pfizer's oncology revenues grew 9% in the first half of 2025, driven by various drugs, while AbbVie's oncology revenues rose 4.2% to $3.3 billion [8] Financial Performance and Valuation - AbbVie's stock has increased by 21.2% this year, outperforming the industry [10] - The company's shares trade at a price/earnings ratio of 15.54, higher than the industry average of 14.64 [13] - The Zacks Consensus Estimate for 2025 earnings has slightly decreased to $12.02 per share, while the estimate for 2026 has increased to $14.31 per share [16]